Companies › Ocumension Therapeutics (Suzhou)
1 active drug program in 1 registered trial: 1 Phase 3; Ophthalmology; next expected readout Jan 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| OT202 Unclear mechanism for dry eye treatment | – | Phase 3 | Dry Eye | Jan 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07740564 | OT202 | Phase 3 | Dry Eye | Ophthalmology | Jan 2029 |
No annotated target.
–
ReGenTree Ocus Innovation Ireland Alkeus Pharmaceuticals Laboratorios Sophia S.A de C.V. Cloudbreak Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.